生物制剂时代银屑病关节炎的疾病负担:比利时流行病学银屑病关节炎研究数据
该研究在比利时17个中心招募461例符合CASPAR标准的银屑病关节炎患者,纵向随访2年。
要点
- 73.5%的患者为外周与中轴联合受累,13.7%有髋关节受累。
- 入组时42.7%无压痛关节、58.8%无肿胀关节,但13.7%仍有指炎、24.1%仍有附着点炎。
核心结论
- 尽管已有包括抗TNF在内的多种治疗选择,相当数量银屑病关节炎患者仍存在活动性疾病和高疾病负担。
研究设计与样本
- 比利时17个学术与非学术中心开展纵向观察性研究,招募符合CASPAR标准的银屑病关节炎患者,计划基线、1年、2年三次访视。
- 共纳入461例患者,收集人口学、临床数据、患者报告结局及手足年检X线、脊柱基线与2年X线。
主要发现
- 73.5%的患者为外周与中轴联合受累,13.7%有髋关节受累,83.9%为斑块状银屑病。
- 入组时42.7%无压痛关节、58.8%无肿胀关节,13.7%有指炎、24.1%有附着点炎。
- 平均HAQ评分为0.7,32.5%的患者HAQ正常(<0.3)。
临床怎么用
- 在生物制剂可及的时代,仍需关注银屑病关节炎患者中持续存在的活动性疾病与高疾病负担,优化治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To characterize the frequency of PsA subtypes, estimate the severity based on damage and inflammation and estimate the impact of PsA on patients' health-related quality of life. METHODS: We conducted a longitudinal observational study in 17 academic and non-academic centres in Belgium. Patients with PsA fulfilling Classification Criteria for Psoriatic Arthritis were recruited. Three visits were scheduled: at baseline (T0), at 1 year (±1 month; T1) and at 2 years (±1 month; T2) of follow-up. Demographics, clinical data and patient-reported outcome measures were collected at T0, T1 and T2. X-rays of the hands and feet were collected yearly (T0, T1 and T2). X-rays of the spine were collected at T0 and T2. Here we report on the burden of disease based on the clinical data and patient-reported outcomes. RESULTS: A total of 461 patients were recruited; 73.5% had combined peripheral and axial involvement and 13.7% had hip involvement. Plaque psoriasis was predominant (83.9%). At inclusion, 42.7% and 58.8% had no tender or swollen joints, respectively. Dactylitis and enthesitis were still present in 13.7% and 24.1% of the patients, respectively. Patients was treated with DMARDs (68%) and/or anti-TNF (44.2%). Forty-three per cent of the patients had a state of minimal disease activity and 62% considered the actual state as satisfactory. The mean HAQ score was 0.7%, with 32.5% of patients having a normal score (<0.3). CONCLUSION: Despite the availability of different treatment options, including biologics (anti-TNF), a substantial number of patients have active disease and have a high disease burden.
引用
- de Vlam K, Steinfeld S, Toukap AN, et al. The burden of psoriatic arthritis in the biologics era: data from the Belgian Epidemiological Psoriatic Arthritis Study. Rheumatology (Oxford). 2021. PMID: 33710278. doi:10.1093/rheumatology/keab233
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。